Market closed
Capricor/$CAPR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
Ticker
$CAPR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
102
Website
Capricor Metrics
BasicAdvanced
$860M
Market cap
-
P/E ratio
-$1.07
EPS
4.02
Beta
-
Dividend rate
Price and volume
Market cap
$860M
Beta
4.02
52-week high
$21.01
52-week low
$2.87
Average daily volume
1.7M
Financial strength
Current ratio
4.192
Quick ratio
4.173
Long term debt to equity
1.223
Total debt to equity
2.415
Management effectiveness
Return on assets (TTM)
-34.73%
Return on equity (TTM)
-102.63%
Valuation
Price to revenue (TTM)
25.862
Price to book
52.61
Price to tangible book (TTM)
52.61
Price to free cash flow (TTM)
-15.674
Growth
Revenue change (TTM)
65.33%
Earnings per share change (TTM)
-6.71%
3-year revenue growth (CAGR)
324.93%
3-year earnings per share growth (CAGR)
9.64%
What the Analysts think about Capricor
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Capricor Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Capricor Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Capricor News
AllArticlesVideos
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·1 week ago
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $860M as of November 22, 2024.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of November 22, 2024.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 4.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.